Lexicon Pharmaceuticals Overview
- Founded
-
1995

- Status
-
Public
- Employees
-
87

- Stock Symbol
-
LXRX

- Investments
-
3
- Share Price
-
$2.24
- (As of Tuesday Closing)
Lexicon Pharmaceuticals General Information
Description
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Contact Information
- 2445 Technology Forest Boulevard
- 11th Floor
- The Woodlands, TX 77381-1160
- United States
Lexicon Pharmaceuticals Timeline
Lexicon Pharmaceuticals Stock Performance
(As of Tuesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$2.24 | $2.17 | $1.31 - $3.48 | $410M | 189M | 378K | -$0.62 |
Lexicon Pharmaceuticals Financials Summary
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 416,396 | 479,932 | 393,345 | 389,850 |
Revenue | 125 | 298 | 23,995 | 322,073 |
EBITDA | (95,376) | (86,798) | (43,863) | 145,099 |
Net Income | (97,061) | (87,758) | (58,574) | 130,133 |
Total Assets | 191,685 | 136,909 | 203,788 | 417,715 |
Total Debt | 30,628 | 2,279 | 12,810 | 245,736 |
Lexicon Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Lexicon Pharmaceuticals Comparisons
Industry
Financing
Details
Lexicon Pharmaceuticals Competitors (104)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
CymaBay Therapeutics | Formerly VC-backed | Newark, CA | 00 | 00000 | 00000000 | 00000 |
0000000 | Formerly PE-Backed | Boston, MA | 000 | 00000 | 000000&0 | 00000 |
000000 00000000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000&0 | |
00000 000000000000 | Formerly VC-backed | Foster City, CA | 000 | 00000 | 000000000 | 00000 |
00000 000000000000 | Formerly VC-backed | San Francisco, CA | 00 | 00000 | 000000&0 | 00000 |
Lexicon Pharmaceuticals Patents
Lexicon Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20220370485-A1 | Compounds and methods for treating or preventing cardiovascular diseases and conditions | Pending | 14-Jan-2021 | 0000000000 | |
AU-2021259419-A1 | Aak1 inhibitors for use in treating viral infections | Pending | 21-Apr-2020 | 0000000000 | |
CA-3175970-A1 | Aak1 inhibitors for use in treating viral infections | Pending | 21-Apr-2020 | 0000000000 | |
US-20220054464-A1 | Compounds and methods for treating viral infections | Pending | 21-Apr-2020 | 0000000000 | |
AU-2021258128-A1 | 4-(3-(pyridin-3-yl)pyrazolo(1,5-a)pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections | Pending | 21-Apr-2020 | A61K31/519 |
Lexicon Pharmaceuticals Executive Team (17)
Lexicon Pharmaceuticals Board Members (9)
Name | Representing | Role | Since |
---|---|---|---|
0000 0000 00 | Self | Board Member | 000 0000 |
00000000000 000000 | The Invus Group | Board Member | 000 0000 |
00000 000000000 | Self | Board Member | 000 0000 |
000000 00000 | Self | Board Member | 000 0000 |
000000 00000 | Lexicon Pharmaceuticals | Chief Executive Officer & Board Member | 000 0000 |
Lexicon Pharmaceuticals Signals
Lexicon Pharmaceuticals Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Lexicon Pharmaceuticals Investments & Acquisitions (3)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000000 0000 | 02-Aug-2010 | 0000000000 | 0000 | Pharmaceuticals | 000000 00 |
00000000 0000 | 01-Jun-2007 | 00000 0000 | Pharmaceuticals | 000000 00 | |
Coelacanth Chemical | 12-Jul-2001 | Merger/Acquisition | 0000 | Pharmaceuticals | 000000 00 |
Lexicon Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 25, 2022
25.38 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,613
Rank
Percentile

Pharmaceuticals
Industry
00 of 1,004
Rank
Percentile

Biotechnology
Subindustry
00 of 462
Rank
Percentile
